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Letters to the EditorReply to the Editor:
We appreciate the thorough review
of our 2-year data after transcatheter
aortic valve implantation (TAVI).
However, we would like to precisely
differentiate between early results
(30-day mortality, 11.5%; stroke,
2.6%; myocardial infarction, 1.8%)
and cumulative incidence of events at
2 years (stroke, 6.6%; myocardial in-
farction, 2.7%). In addition, it has to
be taken into account that the pub-
lished series includes our very first
TAVI experience starting in 2007,
when there was limited worldwide
knowledge on these new procedures.
Having performed now more than
700 TAVI cases, we consistently see
30-day mortality rates of less than
4% during the recent years. Compari-
sons with surgical results are difficult
as long as patient populations are notThe Journalrandomized. The predominant aim of
our studywas to demonstrate the event
rate up to 2 years beyond procedural
results, which, in our eyes, is low and
justifies TAVI in all high-risk patients
and octogenarians. We disagree with
the title of your comment, because
we do not advocate treating younger,
lower-risk patients with TAVI.
In response to your concern with
porcelain aorta, we think that in a pa-
tient population referred for TAVI
there might be a cumulation of all pa-
tients with porcelain aorta who would
never have been sent for AVR. We
completely agree that concerns about
durability of the new transcatheter
prostheses should argue against im-
planting these new prostheses into
younger, lower-risk patients until
longer-term data are available. Other
specific TAVI complications such asof Thoracic and Cardiovascular Surgeparavalvular leak must be analyzed
as well for long-term impact.
To repeat the conclusion stated in our
article, TAVI can be considered the
treatment of choice for aortic valve ste-
nosis in elderly patients with increased
risk for surgery with a heart–lung ma-
chine on the basis of our results. We
do not expand indications to younger,
lower-risk patients at present. Decision
making is individually performed by
a multidisciplinary team at our center,
taking into account the age, comorbid-
ities, and frailty of the patients.
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